Drug resistant tuberculosis is a major public health concern. With the introduction of Xpert MTB/RIF and other technologies, early diagnosis is becoming possible. Through the intensive work of countries and partners, access to treatment has been scaled up in most settings.
Still, with the exception of a few settings, treatment success of multidrug resistant TB cases is suboptimal. Patients are often on long treatment regimens with various adverse events. Recently two new medicines, bedaquiline and delamanid were approved for use under specific conditions. A new short treatment regimen has been piloted in some settings and is showing promising results.
Joining us to discuss these new developments from March 24 – 28 are:
• Dr Aung Maug, Bangeladesh
• Dr Mamel D. Quelapio, The Philippines
• Dr Dalene von Delft, South Africa
• Dr Arnaud Trébucq, France
• Dr Masoud Dara, Belgium
Please feel free to start sharing questions and thoughts now. We look forward to this discussion.